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Received 8 July 2008; revised 24 July 2008; accepted 29 November 2008AbstractDocetaxel, a semi-synthetic taxane analogue, is used effectively in the treatment of metastatic prostate cancer. Zoledronic acid, the most
potent member of bisphosphonates, has shown pleiotropic anti-tumoral effects on prostate cancer cells. We have explored the possible additive/
synergistic effects and the apoptotic pathways induced by combination treatment of docetaxel and zoledronic acid in hormone and drug
refractory, PC-3 and DU-145 prostate cancer cells. Combination of docetaxel and zoledronic acid synergistically inhibits cell growth in PC-3 and
DU-145 cells. Moreover, this effect was due to downregulation of antiapoptotic protein Bcl-2 in PC-3 and DU-145 cells. In conclusion,
docetaxel/zoledronic acid combination is potentially a novel and effective approach for the treatment of prostate cancer.
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Prostate cancer is a worldwide significant health problem
because of its high incidence and mortality particularly in
elderly men, while the androgen-independent state of the
disease has the worst prognosis. There is no standard treatment
modality for this condition. Therefore, it is vitally important to
explore novel agents in order to treat androgen-independent
forms of the disease effectively (Zhao et al., 2004).
In the 1980s, docetaxel, a semi-synthetic taxane analogue
from the European yew (Taxus baccata) was identified.
Approximately 10 years ago, after in vitro studies, docetaxel
was introduced to be an effective treatment option for
androgen-independent prostate cancer (Gligorov and Lotz,* Corresponding author. Tel.: þ90 232 390 39 06; fax: þ90 232 374 73 21.
E-mail address: ruchan.uslu@ege.edu.tr (R. Uslu).
1065-6995/$ - see front matter  2008 International Federation for Cell Biology.
doi:10.1016/j.cellbi.2008.11.0112004; Hanauske et al., 1992). As the results of clinical studies
of its effect on prostate cancer, docetaxel is currently approved
as the most active agent used in the treatment of metastatic
prostate cancer (Berthold et al., 2008). Docetaxel binds to
tubulin subunits and inhibits the disassembly of microtubules
that normally occurs during cell cycle progression. It can also
induce apoptosis significantly through inactivating the anti-
apoptotic Bcl-2 protein by its phosphorilation (Haldar et al.,
1997).
Zoledronic acid is the most potent member of bisphosph-
onate family used mainly for the treatment of skeletal
metastases of different tumor types, including prostate cancer
(Corey et al., 2003). Furthermore, there is strong evidence that
zoledronic acid also has anti-tumoral activities on many types
of human cancers via a variety of mechanisms, including
growth factor release, cell adhesion, antiangiogenic effects and
apoptosis. Several in vitro studies have indeed demonstratedPublished by Elsevier Ltd. All rights reserved.
240 B. Karabulut et al. / Cell Biology International 33 (2009) 239e246varying antiproliferative and cytostatic effects of zoledronic
acid on prostate cancer cells (Dumon et al., 2004; Lee et al.,
2001; Oades et al., 2003).
Based on these data, we have explored the possible addi-
tive/synergistic cytotoxic and apoptotic effects of combination
treatment of docetaxel and zoledronic acid in hormone-
refractory PC-3 and DU-145 prostate cancer cells. We have
also examined for the apoptotic pathways induced in these
cells exposed to docetaxel or zoledronic acid and combination
of both. In this study, we tried to provide a novel drug
combination for the treatment of hormone-refractory prostate
cancer.
2. Materials and methods2.1. ChemicalsCell culture supplies were obtained from Biological
Industries (Kibbutz Beit Haemek, Israel). Zoledronic acid was
a generous gift from Novartis Pharmaceuticals Inc. (Basel,
Switzerland). Docetaxel was obtained from Sigma Chemical
Co (USA). The stock solution of zoledronic acid was prepared
at a concentration of 10 mM in distilled water and aliquots
were stored in 20 C. Stock solution of docetaxel (10 mM)
was prepared in DMSO and the DMSO concentration in the
assay did not exceed 0.1%. All other chemicals, unless
mentioned, were obtained from Sigma. Anti-Bcl-2 antibody
was obtained from Millipore Upstate USA (Charlottesville,
VA).2.2. Cell lines and culture conditionsHuman PC-3 and DU-145 prostate cancer cells were
obtained from ICLC (Genova, Italy). The cells were grown in
RPMI-1640 supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 1% L-glutamine, 1% penicillinestrep-
tomycin. Both cells were grown in incubators at 37 C in the
presence of 5% CO2.2.3. XTT cytotoxicity assayThe cytotoxic effect of docetaxel or zoledronic acid and
their combination on PC-3 and DU-145 cells were evaluated
by XTT cell proliferation kit (Roche Applied Science, Man-
nheim, Germany). Cells (104 cells/well) were plated in a 96-
well plate in 200 ml culture medium in the absence or presence
of increasing concentrations of agents after verifying cell
viability by trypan blue exclusion test. After 72 h of incuba-
tion, 50 ml of XTT labeling mixture was added to each well
and incubated for 4 h. The optical density was measured at
450 nm with a reference wavelength at 650 nm in a microplate
reader (Beckman Coulter, DTX 880 Multimode Reader).2.4. DNA fragmentation analysesApoptosis was evaluated by ELISA using Cell Death
Detection ELISAPLUS kit (Roche Applied Science,Mannheim, Germany) and was confirmed by measuring the
enzyme activity of caspase 3/7. The relative amounts of
mono- and oligonucleosomes generated from the apoptotic
cells were quantified using monoclonal antibodies directed
against DNA and histones by ELISA. Briefly, cytoplasmic
fraction of the untreated control and zoledronic acid or
docetaxel and the combination of both treated cells were
transferred onto a streptavidin-coated plate and incubated for
2 h at room temperature with a mixture of peroxidase conju-
gated anti-DNA and biotin labeled antihistone. The plate was
washed thoroughly, incubated with 2,29-azino-di-[3-ethyl-
benzthiazolinesulfonate] diammonium salt (ABTS) and finally
the absorbance was read at 405 nm with a reference wave-
length at 490 nm (Beckman Coulter, DTX 880 Multimode
Reader). All the experiments were performed in duplicate in
enzyme-linked immunosorbent assay (ELISA) assays.2.5. Caspase 3/7 enzyme activity assayThe Caspase-Glo 3/7 assay (Promega, Madison, WI) was
used to measure caspase 3/7 enzyme activity according to the
manufacturer’s instructions. PC-3 and DU-145 cells at 104
cells/well were plated in a 96-well plate in 100 ml culture
medium in the absence or presence of increasing concentra-
tions of docetaxel or zoledronic acid and the combination of
both. 100 ml of Caspase-Glo 3/7 reagent was added to each
well and incubated at room temperature for 1 h. Finally, the
luminescence of each sample was measured at luminometer
(Beckman Coulter, DTX 880 Multimode Reader).2.6. Western blot analysisPC-3 and DU-145 cells were grown for 72 h in the absence
or presence of docetaxel or zoledronic acid, or a combination
of both at 37 C. To prepare cell lysates for Western immu-
noblot analysis, cell pellets were lysed in buffer containing
20 mM Tris(tris(hydroxymethyl)aminomethane)eHCl (pH
8.0), 137 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM
Na3VO4, 25 mM glycerophosphate and phosphatase inhibitor
cocktail 1 (Sigma, USA). After centrifugation at 14,000 g for
15 min, protein concentrations were quantitated in duplicate
by the Bradford method (Bio-Rad Laboratories, Hercules,
CA). Equal amounts of protein were separated on an SDS-
polyacrylamide gel electrophoresis (PAGE) and transferred to
polyvinylidene difluoride Immobilon-P membranes (Bio-Rad
Laboratories, Hercules, CA). The membranes were blocked
with 5% nonfat drymilk prepared in Tris-buffered saline
containing 0.1% Tween 20 (TBST0.1) at room temperature for
1 h and then incubated with primary antibodies diluted either
in 5% BSA for Bcl-2 protein detection at room temperature for
1 h. Dilutions of primary antibodies were prepared according
to the manufacturer’s instructions. Following several washes in
TBST, membranes were incubated with appropriate secondary
antibodies (1:2000 dilution, Millipore Upstate USA, Charlot-
tesville, VA) at room temperature for 1 h. The protein bands
recognized by the antibodies were visualized by the Kodak
Gel Logic 1500 Imaging System.
241B. Karabulut et al. / Cell Biology International 33 (2009) 239e2462.7. Statistical analysisThe data were analyzed using GraphPad PRISM software
(version 5) (San Diego, CA, USA). All experiments were set
up in triplicate and the results were expressed as the mean -
 standard deviation (SD). The paired Student’s t-test was
used to compare the differences between paired samples.
Differences were considered significant at P value below 0.05.
Median dose effect analysis was used to assess the interaction
between the agents. The combination index (CI) values (Chou
and Talalay, 1984) were calculated by using Biosoft CalcuSyn
program (Ferguson, MO, USA) and CI was used to express
synergism (CI< 1), additive effect (CI¼ 1), or antagonism
(CI> 1).
3. Results3.1. Antiproliferative effects of docetaxel and zoledronic
acid on PC-3 and DU-145 cellsTo examine antiproliferative effect of docetaxel and zole-
dronic acid for each agent, we incubated PC-3 and DU-145
cells in the absence or presence of increasing concentrations ofFig. 2. A. Effects of zoledronic acid on the growth of PC-3 cells. B. Effects of
zoledronic acid on the growth of DU-145 cells. The IC50 concentration of
zoledronic acid was determined by XTT assay for each cell line as described.
The XTT assays were performed using triplicate samples in at least 2 inde-
pendent experiments. The error bars represent the standard deviations and,
when not seen, they are smaller than the thickness of the lines on the graphs.
Statistical significance was determined using two-way analysis of variance,
and was significant (P< 0.05).
Fig. 1. A. Effects of docetaxel on the growth of PC-3 cells. B. Effects of
docetaxel on the growth of DU-145 cells. The IC50 concentration of docetaxel
was calculated from cell proliferation plots. The XTT assays were performed
using triplicate samples in at least 2 independent experiments. The error bars
represent the standard deviations and, when not seen, they are smaller than the
thickness of the lines on the graphs. Statistical significance was determined
using two-way analysis of variance and found to be significant (P< 0.05).docetaxel and zoledronic acid for 24, 48 and 72 h through
XTT cell proliferation assay. PC-3 and DU-145 cells were
exposed to docetaxel (0.01e1000 nM) and zoledronic acid
(5e100 mM) for 24, 48 and 72 h and IC50 values were
calculated from cell proliferation plots. Cytotoxicity was
increased in time and dose-dependent manner for each agent
(data not shown). Highest cytotoxicity was observed at 72 h
for each agent and IC50 values of docetaxel in PC-3 (Fig. 1A)
and DU-145 (Fig. 1B) cells were 12 and 9 nM, respectively. In
zoledronic acid treated PC-3 (Fig. 2A) and DU-145 cells
(Fig. 2B), IC50 values were calculated to be 27 and 92 mM,
respectively, indicating that PC-3 cells were more sensitive toTable 1
Combination index values of docetaxel or zoledronic acid alone and the
combination of both on growth inhibition of PC-3 cells. Combination index
(CI) values were calculated from the XTT cell proliferation assays. The data
represent the mean SD of 3 independent experiments.
Drugs CI Description
Docetaxel (0.01 nM)þ ZA (5 mM) 0.102 Strong synergism
Docetaxel (0.01 nM)þ ZA (10 mM) 0.129 Strong synergism
Docetaxel (0.01 nM)þ ZA (15 mM) 0.300 Synergism
Docetaxel (100 nM)þ ZA (30 mM) 0.229 Synergism
Table 2
Combination index values of docetaxel or zoledronic acid alone and the
combination of both on growth inhibition of DU-145 cells. Combination index
(CI) values were calculated from the XTT cell proliferation assays. The data
represent the meanþ SD of 3 independent experiments.
Drugs CI Description
Docetaxel (0.1 nM)þ ZA (5 mM) 0.026 Strong synergism
Docetaxel (0.1 nM)þ ZA (15 mM) 0.088 Strong synergism
Docetaxel (1 nM)þ ZA (10 mM) 0.025 Strong synergism
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resistant to docetaxel.3.2. Combination of docetaxel and zoledronic acid
suppressed cell growth significantly more than any agent
alone did, in human prostate cancer cellsTo examine the cell growth suppressor effects of docetaxel
and zoledronic acid combination, PC-3 and DU-145 cells were
treated with increasing concentrations of both drugs at the same
time for 24, 48 and 72 h. The synergism or additivity was
calculated via combination index (CI) by using Biosoft Cal-
cusyn Program. CI¼ 1 indicates additive effect, CI> 1 indi-
cates antagonism, CI< 1 indicates synergism and CI< 0.5
shows strong synergy (Chou and Talalay, 1984). Combination
of various concentrations of docetaxel and zoledronic acid at
different time points were evaluated. Results showed that at
72 h, significant growth suppression on human prostate cancer
cells as compared to any agent alone as shown in Tables 1 and 2.
The XTT cell proliferation data indicated that 0.01 nM
docetaxel and 5 mM zoledronic acid resulted in 8 and 10%
decrease in proliferation of PC-3 cells, respectively, while the
combination of both at the same concentrations resulted in
65% decrease in cell proliferation, as compared to untreated
controls (Fig. 3). On the other hand, 0.1 nM docetaxel or 5 mM
zoledronic acid resulted in 5 and 2% decrease in proliferation
of DU-145 cells, respectively, as the combination of both atFig. 3. Effects of docetaxel and zoledronic acid combination on the growth of PC-3
culture. The XTT assays were performed using triplicate samples in at least 2 indep
not seen, they are smaller than the thickness of the lines on the graphs. Statistic
significant (P< 0.05).the same doses caused 70% decrease in cell proliferation as
compared to untreated controls (Fig. 4).
For PC-3 cells exposed to 0.01 nM docetaxel and 5 or
10 mM zoledronic acid, the CI values were calculated to be
0.102 or 0.129, respectively, indicating that the combinations
of docetaxel and zoledronic acid at these concentrations
showed a very strong synergism. Combination index analyses
conducted for DU-145 cells showed that combination treat-
ment of 0.1 nM plus 5 mM zoledronic acid, 0.1 nM docetaxel
plus 15 mM zoledronic acid, and 1 nM docetaxel plus 10 mM
zoledronic acid resulted in strong synergisms.3.3. Effects of the sequential treatmentThe previous findings demonstrated that tumor cells with
docetaxel and zoledronic acid resulted in significant synergy at
72 h. We examined the effect of sequential treatment of PC-3
and DU-145 cells with either docetaxel or zoledronic acid and
subsequent treatment with the second agent. Pretreatment of
tumor cells with docetaxel for 36 h and wash and then treat-
ment for an additional 36 h with zoledronic acid resulted in
synergistic cytotoxicity in both PC-3 and DU-145 cells. Also,
pretreatment of tumor cells with zoledronic acid for 36 h and
wash and then treatment for an additional 36 h with docetaxel
resulted in synergistic cytotoxicity in both PC-3 and DU-145
cells. So we could not show any effect of sequential treatment
on synergy obtained with docetaxel and zoledronic acid (data
not shown).3.4. A significant increase in DNA fragmentation was
detected in response to combination of docetaxel and
zoledronic acid compared to any agent alone in PC-3
and DU-145 cellsTo examine the induction of apoptosis in response to doce-
taxel or zoledronic acid and the combination of both in prostate
cancer cells, we incubated the cells in the presence of the anti-
cancer agents alone or a combination of both for 72 h and thencells. Cytotoxicity was determined by the XTT cell proliferation test in a 72 h
endent experiments. The error bars represent the standard deviations and, when
al significance was determined using two-way analysis of variance and was
Fig. 4. Effects of docetaxel and zoledronic acid combination on the growth of DU-145 cells. Cytotoxicity was determined by the XTT cell proliferation test in
a 72 h culture. The XTT assays were performed using triplicate samples in at least 2 independent experiments. The error bars represent the standard deviations and,
when not seen, they are smaller than the thickness of the lines on the graphs. Statistical significance was determined using two-way analysis of variance, and was
significant (P< 0.05).
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Cell Death Detection Kit (Roche Applied Science, Mannheim,
Germany). The results of DNA fragmentation analyses clearly
showed that combinations of both agents induced apoptosis to
a greater extent than either agent alone.
There were 2.9- or 5.5-fold increase in DNA fragmentation
in 0.1 nM docetaxel or 15 mM zoledronic acid exposed PC-3
cells, respectively, compared with untreated controls, while the
combination of both resulted in a 7.7-fold increase in DNA
fragmentation (Fig. 5). On the other hand, in 1 nM docetaxel
or 10 mM zoledronic acid, or the combination of both on DU-
145 cells, there were 1.8- or 1.7- and 13.1-fold increase in
DNA fragmentation, respectively, as compared to untreated
controls (Fig. 6). The same set of experiments were conducted
with the positive control of kit and have observed a significant
increase in DNA fragmentation (data not shown). The data in
Figs. 5 and 6 show that combination of both drugs inducedFig. 5. Apoptotic effects of docetaxel and zoledronic acid in combination or any age
means of 2 independent experiments. The error bars represent the standard deviatio
graphs. P< 0.05 was considered significant.apoptosis through DNA fragmentation significantly more as
compared to any agent alone.3.5. Caspase 3/7 enzyme activity has been increased in
response to combination of docetaxel and zoledronic
acid more than any agent could induce by itself in human
prostate cancer cellsCaspases are commonly referred to as the hangmen of
apoptosis. The activation of many forms of caspases happens in
many cells undergoing apoptosis. To evaluate whether caspases
play roles in docetaxel and zoledronic acid-induced apoptosis of
PC-3 and DU-145 cells, we measured the levels of caspase 3/7
using Caspase-Glo 3/7 assay. One another important goal of the
examining the changes in caspase 3/7 enzyme activity was to
determine the possible synergistic/additive effects of combina-
tion of docetaxel and zoledronic acid.nt alone on PC-3 cells through DNA fragmentation analyses. The results are the
ns and, when not seen, they are smaller than the thickness of the lines on the
Fig. 6. Apoptotic effects of docetaxel and zoledronic acid in combination or any agent alone alone on DU-145 cells through DNA fragmentation analyses. The
results are the means of 2 independent experiments. The error bars represent the standard deviations and, when not seen, they are smaller than the thickness of the
lines on the graphs. P< 0.05 was considered significant.
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increase in caspase 3/7 enzyme activity in docetaxel or zole-
dronic acid in both PC-3 and DU-145 cells. Specifically, PC-3
cells exposed to 0.1 nM docetaxel and 15 mM zoledronic acid
showed 1.73- or 2.14-fold increase in caspase 3/7 enzyme
activity respectively, as compared to untreated controls, while
their combination resulted in 4.1 times increase in caspase 3/7
enzyme activity (Fig. 7).
A similar set of experiments were conducted with DU-145
cells and the results showed that there were 1.9- and 3-fold
increase in caspase 3/7 enzyme activity in 1 nM docetaxel and
10 mM zoledronic acid applied DU-145 cells, respectively, as
compared to untreated controls. The combination of both
resulted in 18.2 times increase in caspase 3/7 enzyme activity
compared to untreated controls (Fig. 8).Fig. 7. Percent changes in caspase 3/7 enzyme activity in docetaxel and zoledronic
means of 2 independent experiments. The error bars represent the standard deviati
graphs. P< 0.05 was considered significant.3.6. Western-blot analyses showed that combination of
docetaxel and zoledronic acid induces apoptosis through
significantly downregulating antiapoptotic Bcl-2 gene in
human prostate cancer cellsBcl-2 family proteins are overexpressed in many types of
cancers. Although there are different types of proteins in this
family, Bcl-2 protein was specifically recognized to be a ther-
apeutic target in non-Hodgkin’s lymphoma, chronic lympho-
cytic leukemia, prostate cancer, melanoma and some others.
We have clearly shown that in PC-3 cells exposed to 100 nM
docetaxel and 30 mM zoledronic acid, there were significant
decreases in protein levels of Bcl-2 as compared to any agent
alone applied cells (Fig. 9). The same results were also
obtained with DU-145 cells (data not shown). These dataacid combination or any agent alone exposed PC-3 cells. The results are the
ons and, when not seen, they are smaller than the thickness of the lines on the
Fig. 8. Percent changes in caspase 3/7 enzyme activity in docetaxel and zoledronic acid combination or any agent alone exposed DU-145 cells. The results are the
means of 2 independent experiments. The error bars represent the standard deviations and, when not seen, they are smaller than the thickness of the lines on the
graphs. P< 0.05 was considered significant.
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cancer cell apoptosis through downregulating protein levels of
antiapoptotic Bcl-2 gene (Fig. 9).
4. Discussion
Docetaxel has been approved for the treatment of hormone
and drug resistant prostate cancer patients and exhibits its
cytotoxic effect due to decreased proliferation and induction of
apoptosis (Berthold et al., 2008). Zoledronic acid is the most
potent member of bisphosphonates that was shown to be
standard therapy for patients with bone metastasized hormone-
refractory prostate cancer and these agents decrease skeletal
related events (Saad, 2002; Saad et al., 2004). Zoledronic acid
was also shown to have anti-tumoral effects on prostate cancer
cells through induction of apoptosis, inhibition of cell prolif-
eration and angiogenesis (Oades et al., 2003).
Based on the literature, we have examined the possible
synergistic cytotoxic and apoptotic effects of docetaxel and
zoledronic acid combination in hormone-refractory PC-3 and
DU-145 prostate cancer cells. We have clearly shown that
docetaxel and zoledronic acid combination exerts a significant
degree of cytotoxicity on PC-3 and DU-145 prostate carci-
noma cells as compared to any agent alone. These cells are
ideal models to study the effects and mechanisms of various
anticancer agents since they represent the very high aggressive
nature of metastatic human prostate cancers. Our results
revealed that docetaxel and zoledronic acid was significantly
cytotoxic in both PC-3 and DU-145 cells, in a dose- and
time-dependent manner. Antiproliferative concentrations ofFig. 9. Changes in protein levels of antiapoptotic Bcl-2 gene in PC-3 cells exposed
untreated controls by western blotting.combinations of these agents used in our study were in
acceptable doses for in vivo administration. It was also shown
by our studies that apoptosis was induced in prostate carci-
noma cells with significant cytotoxicity, no matter which agent
was applied first. Additionally, we demonstrated that there was
a concentration dependent increase in caspase 3/7 enzyme
activity in prostate carcinoma cells exposed to zoledronic acid
or docetaxel and combinations of both.
In vitro treatment of different human cancer cellswith docetaxel
is associated with induction of apoptosis via phosphorylation and
inactivation of the Bcl-2 protein (Yoshino et al., 2006). Over-
expression of Bcl-2 has been implicated in the progression of
prostate cancer to an androgen-independent stage (Huang et al.,
2003; Lin et al., 2007; Rothermund et al., 2002). By different
groups, it was also found that zoledronic acid inhibits cell prolif-
eration and induces apoptosis through induction of DNA frag-
mentation and downregulation of Bcl-2 (Lee et al., 2001; Dumon
et al., 2004; Caraglia et al., 2007). Based on the mentioned activ-
ities of docetaxel and zoledronic acid, we examined the possible
augmented effects of their combination in PC-3 and DU-145 cells
and searched for the changes in signalling pathways in response to
any agent alone and combinations of both. It was clearly shown by
our western studies that there was a significant decrease in protein
levels of Bcl-2 in PC-3 and DU-145 cells exposed to combinations
ofboth agents as compared toanyagent aloneoruntreated controls.
These results indicate that combinations of both agents induced
apoptosis through downregulating antiapoptotic Bcl-2 protein.
Nowadays, treatment of androgen-independent prostate
cancer still represents a challenge for clinicians. Thus, novel and
effective approaches may provide an important avenue for theto docetaxel or zoledronic acid and the combination of both as compared to
246 B. Karabulut et al. / Cell Biology International 33 (2009) 239e246treatment of these groups of patients. In conclusion, we strongly
suggest that docetaxel and zoledronic acid combination is
a good candidate for this challenging era of daily oncologic
practice. And also, from the clinical point of view, the combi-
nation of docetaxel and zoledronic acid might allow a reduction
in docetaxel doses and, in this way, may diminish docetaxel
adverse effects while maintaining the therapeutic effect in
hormone-refractory prostate cancer patients.References
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